When fatigue occurs in patients taking GLP-1 receptor agonists, it may be directly related to the medication, secondary to the physiological changes these drugs induce (such as reduced caloric intake or altered glucose metabolism), or entirely unrelated to the treatment
Hiramoto B, McCarty TR, Lodhia NA, et al
With personalized treatment plans, licensed provider support, and convenient home delivery, Ro makes clinically proven weight management more accessible.
THURSDAY, March 31, 2022 (HealthDay News) -- Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with increased risks for gallbladder or biliary diseases, with a higher risk for GLP-1 RA use in weight loss, according to a review published online March 28 in JAMA Internal Medicine
For patients with diabetes or other conditions that compromise immune function, a lower threshold for seeking medical advice is appropriate
Persistent nausea that prevents adequate nutrition means your dose is too high or escalated too quickly